REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ SALSPERA, INC. As filed with the U.S. Securities and Exchange Commission on March 20, 2026. Registration Number 333-293121 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ AMENDMENT NO. 3 TO FORM S-1 (Exact Name of Registrant as Specified in its Charter) _______________________________ Delaware 2834 87-4698872 (State or other jurisdiction of incorporation or organiza ...

As filed with the U.S. Securities and Exchange Commission on March 10, 2026. Registration Number 333-293121 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ SALSPERA, INC. (Exact Name of Registrant as Specified in its Charter) _______________________________ | Delaware | 2834 | 87-4698872 | | --- | --- | --- | | (State or other jurisdictio ...

Core Viewpoint - Salspera, a clinical-stage cancer biotechnology company focused on developing live biotherapeutics to stimulate immune responses, has announced its IPO terms, aiming to raise $85 million by issuing 5.7 million shares priced between $14 and $16 each [1] Company Overview - Salspera is headquartered in Cambridge, Massachusetts, and was founded in 2017 [1] - The company is developing a novel class of immunotherapy for solid tumors, referred to as "live biotherapeutics," which are genetically modified agents designed to express specific anti-tumor factors within the tumor microenvironment [1] Lead Project - The lead project, Saltikva, is a genetically modified strain of Salmonella typhimurium that is non-toxic and can be administered orally [1] - This engineered strain is designed to express the human interleukin-2 gene (Salmonella-IL2), potentially increasing the number of NK cells and CD8+ cytotoxic T cells in the tumor microenvironment and peripheral blood [1] - The company is currently focusing on pancreatic cancer and has completed a Phase II trial for patients with stage IV metastatic pancreatic cancer [1] IPO Details - Salspera plans to list on NASDAQ under the ticker symbol TKVA [1] - Kingswood Capital Markets is serving as the exclusive bookrunner for the transaction [1]

As filed with the U.S. Securities and Exchange Commission on February 23, 2026. Registration Number 333-293121 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ SALSPERA, INC. (Exact Name of Registrant as Specified in its Charter) _______________________________ Delaware 2834 87-4698872 (State or other jurisdiction of incorporation or organ ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2026. Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _______________________________ SALSPERA, INC. (Exact Name of Registrant as Specified in its Charter) _______________________________ Delaware 2834 87-4698872 (State or other jurisdiction of incorporation or organization) (Primary Standard ...